Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laina D Mercer

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Lancet. Microbe|November 4, 2022
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsRahnuma Wahid, Laina D Mercer, Tirza De Leon, et al.
Vaccine|February 6, 2023
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized studyRahsan Erdem, Ilse De Coster, Kanchanamala Withanage, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
The Lancet. Global Health|November 15, 2025
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 studyBirahim Pierre Ndiaye, Lucy Koech, Laina D Mercer, et al.
JCI Insight|October 8, 2024
Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infectionRachel L Spreng, Kelly E Seaton, Lin Lin, et al.
The Journal of Infectious Diseases|May 29, 2025
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan AdultsNathanial K Copeland, Lucas Otieno, June Doryne Otieno, et al.
MMWR. Morbidity and Mortality Weekly Report|June 16, 2022
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021Javier Martin, Cara C Burns, Jaume Jorba, et al.
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Lancet. Microbe|November 4, 2022
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsRahnuma Wahid, Laina D Mercer, Tirza De Leon, et al.
Vaccine|February 6, 2023
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized studyRahsan Erdem, Ilse De Coster, Kanchanamala Withanage, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
The Lancet. Global Health|November 15, 2025
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 studyBirahim Pierre Ndiaye, Lucy Koech, Laina D Mercer, et al.
JCI Insight|October 8, 2024
Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infectionRachel L Spreng, Kelly E Seaton, Lin Lin, et al.
The Journal of Infectious Diseases|May 29, 2025
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan AdultsNathanial K Copeland, Lucas Otieno, June Doryne Otieno, et al.
MMWR. Morbidity and Mortality Weekly Report|June 16, 2022
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021Javier Martin, Cara C Burns, Jaume Jorba, et al.
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Pageof 5